Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

Metastatic renal cell carcinoma

  • You have access
    Morphomics Can Predict Oncological Features and Survival of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy
    I-HUNG SHAO, YING-HSU CHANG, TING-WEN SHENG, CHIN-CHIEH TAN, LI-JEN WANG, CHENG-KENG CHUANG, CHUN-TE WU and SEE-TONG PANG
    Anticancer Research October 2021, 41 (10) 5203-5211; DOI: https://doi.org/10.21873/anticanres.15339
  • You have access
    Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer
    SHOTARO YASUOKA, TAKESHI YUASA, RYO FUJIWARA, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, YUKIHIRO KONDO and JUNJI YONESE
    Anticancer Research November 2020, 40 (11) 6493-6497; DOI: https://doi.org/10.21873/anticanres.14671
  • You have access
    Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma
    KIYOSHI TAKAHARA, RYOSUKE ANDO, KENT KANAO, TOSHIKI ITO, HIDEAKI MIYAKE, MAKOTO SUMITOMO, TAKAHIRO YASUI and RYOICHI SHIROKI
    Anticancer Research August 2020, 40 (8) 4395-4400; DOI: https://doi.org/10.21873/anticanres.14443
  • You have access
    Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report
    LUCAS ZARLING, HAMID EMAMEKHOO, GAURI BHUTANI, TIMOTHY ZIEMLEWICZ, KRISTINA A. MATKOWSKYJ and CHRISTOS E. KYRIAKOPOULOS
    Anticancer Research March 2020, 40 (3) 1527-1534; DOI: https://doi.org/10.21873/anticanres.14098
  • You have access
    The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma
    JIAN-RI LI, YEN-CHUAN OU, CHENG-KUANG YANG, SHIAN-SHIANG WANG, CHUAN-SU CHEN, HAO-CHUNG HO, CHEN-LI CHENG, CHI-REI YANG, CHENG-CHE CHEN, SHU-CHI WANG, CHIA-YEN LIN, SHENG-CHUN HUNG, CHIANN-YI HSU and KUN-YUAN CHIU
    Anticancer Research September 2018, 38 (9) 5339-5345; DOI: https://doi.org/10.21873/anticanres.12861
  • You have access
    Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years
    HIDEAKI MIYAKE, RYOTA AKI, YUTO MATSUSHITA, KEITA TAMURA, DAISUKE MOTOYAMA, TOSHIKI ITO, TAKAYUKI SUGIYAMA and ATSUSHI OTSUKA
    Anticancer Research June 2018, 38 (6) 3593-3599; DOI: https://doi.org/10.21873/anticanres.12633
  • You have access
    Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors
    PAWEL CHROM, RAFAL STEC, LUBOMIR BODNAR and CEZARY SZCZYLIK
    Anticancer Research January 2018, 38 (1) 359-365;
  • You have access
    Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma
    HIDEAKI MIYAKE, SATOSHI IMAI, KEITA TAMURA, TAKAYUKI SUGIYAMA, HIROSHI FURUSE, SEIICHIRO OZONO and MASATO FUJISAWA
    Anticancer Research March 2017, 37 (3) 1523-1528;
  • You have access
    Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma
    YUTA TAKEZAWA, KOUJI IZUMI, YUSUKE SHIMURA, MAOLAKE AERKEN, ARIUNBOLD NATSAGDORJI, MASASHI IIJIMA, KAZUYOSHI SHIGEHARA, TAKAHIRO NOHARA, KAZUTAKA NARIMOTO, YOSHIFUMI KADONO, YASUHIDE KITAGAWA, HIROYUKI KONAKA and ATSUSHI MIZOKAMI
    Anticancer Research September 2016, 36 (9) 4961-4964;
  • You have access
    No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma
    AKIRA MIYAZAKI, HIDEAKI MIYAKE, KEN-ICHI HARADA and MASATO FUJISAWA
    Anticancer Research May 2015, 35 (5) 3067-3073;

Pages

  • Next
  • 1
  • 2
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire